Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume -, Issue -, Pages 1-4
Publisher
Informa UK Limited
Online
2021-05-06
DOI
10.1080/21645515.2021.1920272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
- (2021) Katharina Wørzner et al. EBioMedicine
- The challenge of avidity determination in SARS‐CoV‐2 serology
- (2021) Georg Bauer et al. JOURNAL OF MEDICAL VIROLOGY
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Avidity assay to test functionality of anti-SARS-Cov-2 antibodies
- (2021) Emanuelle Baldo Gaspar et al. VACCINE
- Understanding of COVID‐19 based on current evidence
- (2020) Pengfei Sun et al. JOURNAL OF MEDICAL VIROLOGY
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury
- (2020) Yingxia Liu et al. National Science Review
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
- (2020) Yuan Huang et al. ACTA PHARMACOLOGICA SINICA
- OMV Vaccines and the Role of TLR Agonists in Immune Response
- (2020) Francesca Mancini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
- (2020) Gian Marco Casillo et al. PHARMACOLOGICAL RESEARCH
- Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2
- (2020) Yi Zhang et al. Nature Communications
- The socio-economic implications of the coronavirus pandemic (COVID-19): A review
- (2020) Maria Nicola et al. International Journal of Surgery
- Immune responses of meningococcal B outer membrane vesicles in middle-aged mice
- (2020) Gabriela Trzewikoswki de Lima et al. Pathogens and Disease
- Mechanisms of SARS-CoV-2 transmission and pathogenesis
- (2020) Andrew G. Harrison et al. TRENDS IN IMMUNOLOGY
- Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
- (2020) Indu Khatri et al. Frontiers in Immunology
- GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines
- (2020) Francesca Micoli et al. Vaccines
- Cytokine profile and disease severity in patients with COVID-19
- (2020) Ali Ghazavi et al. CYTOKINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
- (2019) Puthupparampil V. Scaria et al. npj Vaccines
- Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B
- (2018) Fernanda Ayane de Oliveira Santos et al. IMMUNOBIOLOGY
- A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model
- (2018) Kui Xu et al. PLoS One
- Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection
- (2017) Hannah C. Watkins et al. MOLECULAR THERAPY
- A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles
- (2017) Hannah C. Watkins et al. VACCINE
- Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles
- (2017) Alberto Grandi et al. Frontiers in Oncology
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
- (2013) Miguel O’Ryan et al. DRUGS
- Immunization with Escherichia coli Outer Membrane Vesicles Protects Bacteria-Induced Lethality via Th1 and Th17 Cell Responses
- (2013) O. Y. Kim et al. JOURNAL OF IMMUNOLOGY
- Evidence based route of administration of vaccines
- (2011) Ian F. Cook Human vaccines & immunotherapeutics
- Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand
- (2011) Richard Arnold et al. VACCINE
- Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming
- (2011) Dong Ho Lee et al. VACCINE
- Delivery of foreign antigens by engineered outer membrane vesicle vaccines
- (2010) D. J. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2
- (2008) O. Koeberling et al. Clinical and Vaccine Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now